Search

Displaying results 871 - 880 of 2817 in total
  1. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  2. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.

  3. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

  4. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  5. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: IVABRADINA DOC GENERICI
  7. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia (HoFH) under the brand

  9. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  10. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]